- Home
- CIFR vs IDYA Comparison
CIFR vs IDYA Comparison
Compare CIFR & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIFR
- IDYA
- Stock Information
- Founded
- CIFR 2021
- IDYA 2015
- Country
- CIFR United States
- IDYA United States
- Employees
- CIFR N/A
- IDYA N/A
- Industry
- CIFR Investment Bankers/Brokers/Service
- IDYA Biotechnology: Pharmaceutical Preparations
- Sector
- CIFR Finance
- IDYA Health Care
- Exchange
- CIFR Nasdaq
- IDYA Nasdaq
- Market Cap
- CIFR 2.1B
- IDYA 2.2B
- IPO Year
- CIFR N/A
- IDYA 2019
- Fundamental
- Price
- CIFR $5.14
- IDYA $24.34
- Analyst Decision
- CIFR Strong Buy
- IDYA Strong Buy
- Analyst Count
- CIFR 11
- IDYA 13
- Target Price
- CIFR $7.67
- IDYA $51.36
- AVG Volume (30 Days)
- CIFR 24.6M
- IDYA 1.1M
- Earning Date
- CIFR 08-07-2025
- IDYA 08-05-2025
- Dividend Yield
- CIFR N/A
- IDYA N/A
- EPS Growth
- CIFR N/A
- IDYA N/A
- EPS
- CIFR N/A
- IDYA N/A
- Revenue
- CIFR $158,849,000.00
- IDYA $7,000,000.00
- Revenue This Year
- CIFR $88.30
- IDYA $101.44
- Revenue Next Year
- CIFR $63.63
- IDYA $263.37
- P/E Ratio
- CIFR N/A
- IDYA N/A
- Revenue Growth
- CIFR 0.11
- IDYA N/A
- 52 Week Low
- CIFR $1.86
- IDYA $13.45
- 52 Week High
- CIFR $7.77
- IDYA $40.74
- Technical
- Relative Strength Index (RSI)
- CIFR 47.21
- IDYA 52.57
- Support Level
- CIFR $4.67
- IDYA $22.09
- Resistance Level
- CIFR $5.10
- IDYA $24.75
- Average True Range (ATR)
- CIFR 0.36
- IDYA 1.25
- MACD
- CIFR -0.12
- IDYA -0.13
- Stochastic Oscillator
- CIFR 27.35
- IDYA 40.05
About CIFR Cipher Mining Inc.
Cipher Mining Inc ia an emerging technology company that operates in the Bitcoin mining ecosystem in the United States. The company is developing a cryptocurrency mining business, specializing in Bitcoin. The company is expanding and strengthening the Bitcoin network's critical infrastructure in the United States.
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.